4-(溴乙酰基)吡啶氢溴酸盐 | 5349-17-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(溴乙酰基)吡啶氢溴酸盐
• 中文别名: 4-(溴乙酰基)吡啶盐酸；2-溴-1-(4-吡啶基)乙酮；4-(溴乙酰基)吡啶溴酸盐；2-溴-1-(4-吡啶基)-1-乙酮氢溴酸；4-溴乙酰基吡啶氢溴酸盐
• 英文名称: 4-bromoacetylpyridine hydrobromide
• 英文别名: 2-bromo-1-(pyridin-4-yl)ethanone hydrobromide；2-bromo-1-(pyridin-4-yl)ethan-1-one hydrobromide；4-(bromoacetyl)pyridinium bromide；2-bromo-1-(4-pyridyl)ethan-1-one hydrobromide；2-bromo-1-(4-pyridyl)ethanone hydrobromide；2-bromo-1-(4-pyridinyl)-1-ethanone hydrobromide；2-Bromo-1-pyridin-1-ium-4-ylethanone;bromide；2-bromo-1-pyridin-1-ium-4-ylethanone;bromide
• CAS: 5349-17-7
• 化学式: BrH*C₇H₆BrNO
• mdl: MFCD02681893
• 分子量: 280.947
• InChiKey: RGALBQILADNMKA-UHFFFAOYSA-N

物化性质

• 熔点：
  194 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.04
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  30
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H314
• 储存条件：
  | 2～8°C |

SDS

Name:	2-Bromo-1-(4-pyridinyl)-1-ethanone hydrobromide 97% Material Safety Data Sheet
Synonym:
CAS:	5349-17-7

Section 1 - Chemical Product MSDS Name:2-Bromo-1-(4-pyridinyl)-1-ethanone hydrobromide 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5349-17-7	2-Bromo-1-(4-pyridinyl)-1-ethanone hyd	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.) Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5349-17-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7Br2NO
Molecular Weight: 280.95

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5349-17-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-1-(4-pyridinyl)-1-ethanone hydrobromide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5349-17-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5349-17-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5349-17-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用可作为合成头孢洛林酯的关键中间体。具体方法如下：在反应瓶中加入乙酸乙酯720克和4-乙酰基吡啶121.1克，搅拌均匀后，在20~30℃的温度下分批加入NBS 195.8克；加完后，缓慢升温至50~60℃，通过薄层色谱监控原料反应，约10小时后反应完毕。随后降温至10~20℃，充分析晶，过滤，并用600克去离子水打浆洗涤一次。再次过滤、烘干，最终得到类白色4-（溴乙酰基）吡啶氢溴酸盐272.6克，摩尔收率为97.0%，熔点为194~195℃。

反应信息

• 作为反应物：
  描述：

  4-(溴乙酰基)吡啶氢溴酸盐 在 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 甲苯 为溶剂， 反应 17.0h， 生成 PFK158游离
  参考文献：
  名称：

  [EN] PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC
  [FR] INHIBITEUR DE PFKFB3 ET PROCÉDÉS D'UTILISATION EN TANT QUE PRODUIT THÉRAPEUTIQUE ANTICANCÉREUX

  摘要：

  本文提供了一种新的化合物，即(E)-1-(吡啶-4-基)-3-(7-(三氟甲基)喹啉-2-基)-丙-2-烯-1-酮。 (E)-1-(吡啶-4-基)-3-(7-(三氟甲基)喹啉-2-基)-丙-2-烯-1-酮是6-磷酸果糖-2-激酶/果糖-2,6-双磷酸酶3 (PFKFB3)的抑制剂，在体外和体内具有惊人的优越疗效和药效学特性。还提供了包括该化合物的制药组合物以及在体内治疗癌症和肿瘤，以及抑制细胞中糖酵解通量和PFKFB3酶活性的方法。

  公开号：

  WO2013148228A1
• 作为产物：
  描述：

  4-乙酰吡啶 在 溴 作用下， 以 氯仿 为溶剂， 生成 4-(溴乙酰基)吡啶氢溴酸盐
  参考文献：
  名称：

  新型吡啶基-羰基噻唑类化合物的合成，抗氧化和抗菌性能

  摘要：

  海洋化合物树状蛇毒碱首先从被膜类（Dendrodo grossularia）获得。它有一个五元环，也就是一个杂环噻二唑，在自然资源中很少见到。随着其生物学活性，最近已经研究了新的类似物。用于该研究的类似物的合成是通过不常见的噻唑封闭，包括亚甲基-羰基缩合实现的。通过NMR（1，13 C）和HRMS光谱阐明结构。作为生物碱衍生物，通过DPPH和FRAP分析评估了抗氧化性能，并通过微量稀释法评估了其抗菌效果。在这些系列中，3bc-3cf的抗氧化活性比具有3或4-吡啶基取代基的抗氧化活性高。对于含2-吡啶基的基团，2-吡啶基的活性较小，这可能是分子内相互作用的结果。在250μg/ mL下未观察到针对革兰氏阴性细菌的活性。3ae和3ce显示出对金黄色葡萄球菌的活性为64μg/ mL，而3ae显示出对表皮葡萄球菌革兰氏阳性菌的活性为16μg/ mL。氯霉素以8–16μg/ mL的浓度显示出对所有微生

  DOI：

  10.3906/kim-2008-8

文献信息

• Synthesis of 4- and 5-arylthiazolinethiones as inhibitors of indoleamine 2,3-dioxygenase
  作者：Monaem Balti、Aurélie Plas、Céline Meinguet、Marie Haufroid、Quentin Thémans、Mohamed Lotfi Efrit、Johan Wouters、Steve Lanners

  DOI：10.1016/j.bmcl.2016.06.052

  日期：2017.8

  ring within pocket A of the enzyme. On this basis, chemical modifications were proposed to increase inhibition activity. Synthetic routes had to be adapted and optimized to yield the desired substituted 4- and 5-arylthiazolinethiones. Their biological evaluation shows that 5-aryl regioisomers are systematically less potent than the corresponding 4-aryl analogs. Substitution on the phenyl ring does not

  4-苯基噻唑啉硫酮对人 IDO1 的对接研究表明，环外硫原子与血红素铁的络合进一步被酶口袋 A 内苯环的疏水相互作用增强。在此基础上，提出了化学修饰以增加抑制活性。合成路线必须进行调整和优化以产生所需的取代 4-和 5-芳基噻唑啉硫酮。他们的生物学评估表明，5-芳基区域异构体的效力低于相应的 4-芳基类似物。除 4-Br 和 4-Cl 衍生物外，苯环上的取代不会显着增加抑制效力。
• Sulfonamide derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06359134B1

  公开（公告）日：2002-03-19

  The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.

  本发明提供了一种化合物，该化合物特异性地抑制FXa，口服给药有效，并且用作预防或治疗由血栓或梗死引起的疾病的药物是安全的。本发明的化合物是哌嗪酮的公式： 其中R1是可选地取代的烃基或可选地取代的杂环基；环A是除了被公式：的基团取代的之外的可选地取代的二价含氮杂环基： 和公式的基团： Y是可选地取代的二价烃基或可选地取代的二价杂环基；X是直接键或可选地取代的亚烷基链；Z是（1）与可选地取代的烃基取代的氨基，（2）可选地取代的亚氨基或（3）可选地取代的含氮杂环基；当X是直接键并且Z是可选地取代的6-成员含氮芳香杂环基时，Y是可选地取代的二价烃基或可选地取代的二价不饱和杂环基；或其盐。
• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET MÉTHODES
  申请人：TEMPERO PHARMACEUTICALS INC

  公开号：WO2013019682A1

  公开（公告）日：2013-02-07

  The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

  本发明涉及新型视黄醛酸相关孤儿受体γ（RORγ）调节剂及其在治疗由RORγ介导的疾病中的应用。
• Synthesis and Analgesic Activity of Some Substituted 1-Benzofurans and 1-Benzothiophenes
  作者：Stanislav Rádl、Petr Hezký、Petr Konvička、Ivan Krejčí

  DOI：10.1135/cccc20001093

  日期：——

  2-Benzoyl- and 2-(pyridylcarbonyl)-1-benzofuran-3-amines were prepared from 2-hydroxybenzonitrile and corresponding bromoethanone derivatives. 2-Benzoyl- and 2-(pyridylcarbonyl)-1-benzothiophene-3-amines were prepared analogously from 2-sulfanylbenzonitrile. 2-Benzoyl-1-benzofuran-3-amine treated with acetic anhydride or ethyl chloroformate provided the corresponding N-acetyl or N-ethoxycarbonyl derivatives. These N-activated compounds were alkylated with ethyl bromoacetate to provide ethyl N-acetyl-N-(2-benzoyl-1-benzofuran-3-yl)glycinate and ethyl N-(2-benzoyl-1-benzofuran-3-yl)-N-ethoxycarbonylglycinate, respectively. Their mild hydrolysis gave the corresponding glycine derivatives. Methylation of ethyl N-(2-benzoyl-1-benzofuran-3-yl)carbamate gave the corresponding N-methyl carbamate, which was hydrolyzed to N-methyl-(2-benzoyl-1-benzofuran-3-yl)amine. 2-Benzoyl-7-methoxy-1-benzofuran-3-amine and 2-(4-methoxybenzoyl)-1-benzofuran-3-amine were demethylated with boron tribromide to the corresponding hydroxy derivatives; their O-alkylation with ethyl bromoacetate than gave ethyl [(3-amino-2-benzoyl-1-benzofuran-7-yl)oxy]acetate and ethyl 4-[(3-amino-1-benzofuran-2-yl)carbonyl]phenoxy}acetate, respectively. The mild hydrolysis of these esters provided corresponding acids. Similarly, alkylation of the hydroxy derivatives with (dimethylamino)propyl chloride gave corresponding (dimethylamino)propoxy derivatives. 2-Hydroxybenzonitrile treated with 2-bromo-1-(2-, 3-, or 4-pyridyl)ethan-1-one provided the respective 2-(pyridylcarbonyl)-1-benzofuran-3-amine. Similar 2-(pyridylcarbonyl)-1-benzothiophene-3-amines were prepared analogously from 2-sulfanylbenzonitrile. 2-Benzoyl-3-(bromomethyl)-1-benzofuran treated with dimethylamine, 1-methylpiperazine, and sodium 1-methylpiperidine-4-thiolate gave the corresponding alkylation products. Several compounds were found to exhibit considerable analgesic activity.

  2-苯甲酰基和2-(吡啶甲酰基)-1-苯并呋喃-3-胺是由2-羟基苯甲腈和相应的溴乙酮衍生物制备而成的。类似地，2-苯甲酰基和2-(吡啶甲酰基)-1-苯并噻吩-3-胺是由2-硫代基苯甲腈制备而成的。用乙酸酐或氯甲酸乙酯处理2-苯甲酰基-1-苯并呋喃-3-胺可得到相应的N-乙酰基或N-乙氧羰基衍生物。这些N-活化化合物与溴乙酸乙酯烷基化，得到乙基N-乙酰基-N-(2-苯甲酰基-1-苯并呋喃-3-基)甘氨酸酯和乙基N-(2-苯甲酰基-1-苯并呋喃-3-基)-N-乙氧羰基甘氨酸酯。它们经轻度水解得到相应的甘氨酸衍生物。乙基N-(2-苯甲酰基-1-苯并呋喃-3-基)氨基甲酸酯的甲基化得到相应的N-甲基氨基甲酸酯，后者水解为N-甲基-(2-苯甲酰基-1-苯并呋喃-3-基)胺。2-苯甲酰基-7-甲氧基-1-苯并呋喃-3-胺和2-(4-甲氧基苯甲酰基)-1-苯并呋喃-3-胺经三溴化硼去甲基化得到相应的羟基衍生物；它们与溴乙酸乙酯的O-烷基化反应得到乙基[(3-氨基-2-苯甲酰基-1-苯并呋喃-7-基)氧基]乙酸酯和乙基4-[(3-氨基-1-苯并呋喃-2-基)羰基]苯氧基}乙酸酯，分别。这些酯的轻度水解得到相应的酸。类似地，羟基衍生物与(二甲氨基)丙基氯化物烷基化得到相应的(二甲氨基)丙氧基衍生物。2-羟基苯甲腈与2-溴-1-(2-, 3- 或 4-吡啶基)乙酮反应得到相应的2-(吡啶甲酰基)-1-苯并呋喃-3-胺。类似地，2-(吡啶甲酰基)-1-苯并噻吩-3-胺是由2-硫代基苯甲腈类似地制备而成的。2-苯甲酰基-3-(溴甲基)-1-苯并呋喃与二甲胺、1-甲基哌嗪和硫代-1-甲基哌嗪钠盐反应得到相应的烷基化产物。发现几种化合物具有显著的镇痛活性。
• [EN] P2X4 RECEPTOR MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DU RÉCEPTEUR P2X4
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2015088564A1

  公开（公告）日：2015-06-18

  Provided herein are P2X4 receptor modulating compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including but not limited to, chronic pain, neuropathy, inflammatory diseases and central nervous system disorders.

  本文提供了P2X4受体调节化合物，其合成方法，包含这些化合物的药物组合物，以及它们的使用方法。本文提供的化合物可用于治疗、预防和/或管理各种疾病，包括但不限于慢性疼痛、神经病变、炎症性疾病和中枢神经系统疾病。